543 related articles for article (PubMed ID: 23803690)
1. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
[TBL] [Abstract][Full Text] [Related]
4. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
6. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
Sarantis P; Bokas A; Papadimitropoulou A; Koustas E; Theocharis S; Papakotoulas P; Schizas D; Papalampros A; Felekouras E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208987
[TBL] [Abstract][Full Text] [Related]
8. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
[TBL] [Abstract][Full Text] [Related]
9. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Hidalgo M; Plaza C; Musteanu M; Illei P; Brachmann CB; Heise C; Pierce D; Lopez-Casas PP; Menendez C; Tabernero J; Romano A; Wei X; Lopez-Rios F; Von Hoff DD
Clin Cancer Res; 2015 Nov; 21(21):4811-8. PubMed ID: 26169969
[TBL] [Abstract][Full Text] [Related]
10. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
[TBL] [Abstract][Full Text] [Related]
11. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
13. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
[TBL] [Abstract][Full Text] [Related]
15. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Alvarez R; Musteanu M; Garcia-Garcia E; Lopez-Casas PP; Megias D; Guerra C; Muñoz M; Quijano Y; Cubillo A; Rodriguez-Pascual J; Plaza C; de Vicente E; Prados S; Tabernero S; Barbacid M; Lopez-Rios F; Hidalgo M
Br J Cancer; 2013 Aug; 109(4):926-33. PubMed ID: 23907428
[TBL] [Abstract][Full Text] [Related]
16. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
[TBL] [Abstract][Full Text] [Related]
18. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
